Clinical trials: MYOPATHY
Fibromyalgia
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RALLY (NCT04508621)
- Testing
- TNX-102 SL
- Where
- 36 sites in United States
- Volunteers
- 514 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Musculoskeletal Pain
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
To determine the safety and efficacy of single intra-operative treatment of EB-001 IM injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with subpectoral implants
- Trial name
- NCT03193593
- Testing
- EB-001
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bonti, Inc.
Fibromyalgia, Myofascial Pain Syndromes
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia.
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases
- Trial name
- RE-AFFIRM (NCT02829814)
- Testing
- TNX-102 SL Tablet, 2.8 mg
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Musculoskeletal Pain, Musculoskeletal Strain
Occupational Therapy's Role in Promoting Community Wellness Utilizing Sit-Stand Workstations
The aim of this study is to combat the growing global health issue of sedentary behavior and the associated health consequences of prolonged sitting in the workplace.
- Conditions
- Musculoskeletal Pain, Musculoskeletal Strain, Sedentary Lifestyle
- Trial name
- NCT03052426
- Testing
- Ergotron WorkFit - TL
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- West Virginia University
Post-stroke Shoulder Pain and Spasticity
Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity
The purpose of this study is to evaluate whether botulinum toxin type A injected into muscles around the shoulder is effective in treating shoulder pain and improving function in patients with shoulder pain and involuntary muscle…
- Trial name
- NCT00661089
- Testing
- Botulinum Toxin Type A - OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Acute Musculoskeletal Pain, Chronic Pain
Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults
The investigators have developed a three component intervention to support shared decision-making during the early recovery phase for older adults who present to the emergency department (ED) or orthopedic urgent care with acute…
- Trial name
- BETTER (NCT04118595)
- Testing
- Educational Video, Telecare, Correspondence with Primary Care Provider
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of North Carolina, Chapel Hill
Muscular Dystrophies
A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy
The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
- Trial name
- DMD114044 (NCT01254019)
- Testing
- GSK2402968 6mg/kg/week
- Where
- 47 sites in Argentina, Belgium and 18 more
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Stroke, Muscle Spasticity
Altering Activation Patterns Post-stroke
This study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (AMP) is used to encourage increased…
- Conditions
- Stroke, Muscle Spasticity, Hemiparesis
- Trial name
- NCT02418949
- Testing
- Cyproheptadine, Active Movement Practice (AMP), Passive Cyclical Stretching
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Shirley Ryan AbilityLab
Lateral Epicondylitis
Trial of Blood Flow Restriction Plus Physical Therapy vs. Physical Therapy Alone for Lateral Epicondylitis
Open label randomized controlled trial comparing evidenced based physical/occupational therapy vs. physical/occupational therapy including blood flow restriction tourniquet in the treatment of lateral epicondylitis (tennis elbow).
- Trial name
- NCT03978897
- Testing
- Blood flow restriction tourniquet, Evidence based physical/occupational therapy
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Cleveland Clinic Akron General
Duchenne Muscular Dystrophy
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
- Trial name
- NCT00844597
- Testing
- AVI-4658 for Injection
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sarepta Therapeutics, Inc.
Tennis Elbow
ITU Treatment for Chronic Epicondylitis Musculoskeletal Pain Reduction
This study evaluates the effectiveness, safety and patient tolerance for the use of Intense Therapeutic Ultrasound (ITU) for chronic, subcutaneous lateral Epicondylitis musculoskeletal tissue pain reduction began in July 2015 and…
- Trial name
- ITU (NCT03255733)
- Testing
- Intense Therapeutic Ultrasound Treatment
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Guided Therapy Systems
Muscular Dystrophy, Duchenne
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
- Trial name
- NCT02286947
- Testing
- Eteplirsen
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sarepta Therapeutics, Inc.
Tendinopathy
Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
- Trial name
- NCT03344640
- Testing
- secukinumab
- Where
- 12 sites in United States, Czechia and 3 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Fibromyalgia
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
Evaluation of the effect of combinatorial treatment of fibromyalgia patients (standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care on subjective pain measurement Revised Fibromyalgia Impact…
- Trial name
- NCT04594733
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Duchenne Muscular Dystrophy
Open-label Extension of the HOPE-2 Trial
This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up.
- Trial name
- HOPE-2-OLE (NCT04428476)
- Testing
- Deramiocel (CAP-1002)
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Capricor Inc.
Temporomandibular Disorders (TMD)
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of Temporomandibular Disorders (TMD), which are medical conditions involving the temporomandibular joint (the…
- Trial name
- NCT05262517
- Testing
- Rimegepant
- Where
- 32 sites in United States
- Volunteers
- 126 people
- Sponsor
- Pfizer
Myofascial Pain Syndrome
Efficacy of Photobiomodulation Therapy Using 980nm Versus 635nm Diode Lasers for Treatment of Myofascial Pain
This randomized controlled clinical trial aims to evaluate the efficacy of low-level laser therapy (LLLT) using two different diode laser wavelengths (980 nm and 635 nm) in the treatment of myofascial pain associated with…
- Trial name
- LLLTsEMG (NCT07069764)
- Testing
- Doctor smile 635nm For Arm 1, Doctor smile 980 nm For Arm2
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- National Institute of Laser Enhanced Sciences
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS), otherwise known as Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), is an under-recognized disorder whose cause is not yet understood.
- Conditions
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance
- Trial name
- NCT03674541
- Testing
- Pyridostigmine Bromide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS).
- Conditions
- Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01207492
- Testing
- nilotinib
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Andrew J. Wagner, MD, PhD